Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 39.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 34,857 shares of the company’s stock after acquiring an additional 9,896 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Medpace were worth $10,801,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. RiverPark Advisors LLC acquired a new position in Medpace during the fourth quarter worth about $26,000. Contravisory Investment Management Inc. acquired a new position in Medpace during the fourth quarter worth about $26,000. Altshuler Shaham Ltd acquired a new position in Medpace during the fourth quarter worth about $27,000. FinTrust Capital Advisors LLC acquired a new position in shares of Medpace in the 3rd quarter valued at $30,000. Finally, Rockefeller Capital Management L.P. boosted its position in shares of Medpace by 361.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 143 shares of the company’s stock valued at $30,000 after purchasing an additional 112 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Trading Down 1.0 %

Shares of NASDAQ MEDP opened at $404.77 on Wednesday. Medpace Holdings, Inc. has a one year low of $185.43 and a one year high of $419.42. The firm has a market capitalization of $12.54 billion, a PE ratio of 45.58, a PEG ratio of 2.16 and a beta of 1.38. The business has a 50-day moving average price of $382.54 and a two-hundred day moving average price of $312.99.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 12th. The company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.22 by $0.24. Medpace had a return on equity of 63.98% and a net margin of 15.00%. The firm had revenue of $498.40 million during the quarter, compared to analyst estimates of $498.72 million. During the same period last year, the company posted $2.12 EPS. The business’s quarterly revenue was up 26.5% compared to the same quarter last year. Research analysts anticipate that Medpace Holdings, Inc. will post 10.53 EPS for the current year.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the sale, the vice president now directly owns 15,181 shares in the company, valued at approximately $6,117,943. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the sale, the vice president now directly owns 15,181 shares in the company, valued at approximately $6,117,943. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the sale, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The disclosure for this sale can be found here. In the last ninety days, insiders sold 189,340 shares of company stock worth $76,651,647. 25.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on MEDP shares. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, March 23rd. Robert W. Baird increased their price target on Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a research report on Wednesday, February 14th. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 price target for the company. Finally, UBS Group upgraded Medpace from a “neutral” rating to a “buy” rating and increased their price target for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $382.00.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.